港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

MIRXES-B

30.000

+6.70028.76%

成交量：917.87萬

成交額：2.75億

市值：82.90億

市盈率：- -

高：31.950

開：29.000

低：29.000

收：23.300

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

MIRXES-B

交易所：

SEHK

成立時間：

2014

員工人數：

352

公司地址：

2 Tukang Innovation Grove,#09-02 JTC MedTech Hub,Singapore,Singapore

官網：

http://mirxes.com

郵編：

618305

電話：

傳真：

- -

簡介：

MiRXES Holding Company Limited is a micro ribonucleic acid (miRNA) technology company specializing in early cancer detection and precision medicine. It develops and commercializes accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases. Its segments include Infectious diseases and Early detection and precision multi-omics. Its solutions include cancer screening; clinical sequencing; cancer treatment selection, and infectious diseases. Its core product (namely, GASTROClear), two other commercialized products (namely, LUNGClear and Fortitude), and six product candidates at pre-clinical stage. GASTROClear is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. LUNGClear, its lung cancer screening product candidate, is a detection panel consisting of miRNA biomarkers discovered and verified in multi-center studies. It offers complete COVID-19 testing solutions.

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02629/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02629","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02629\",,,,,undefined,":{"symbol":"02629","market":"HK","secType":"STK","nameCN":"MIRXES-B","latestPrice":30,"timestamp":1747987708030,"preClose":23.3,"halted":0,"volume":9178741,"delay":0,"floatShares":276342331,"shares":276342331,"eps":0,"marketStatus":"未開盤","change":6.7,"latestTime":"05-23 16:08:28","open":29,"high":31.95,"low":29,"amount":274942915,"amplitude":0.126609,"askPrice":30.05,"askSize":300,"bidPrice":30,"bidSize":9400,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1748223000000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":23.3,"openAndCloseTimeList":[[1747963800000,1747972800000],[1747976400000,1747987200000]],"volumeRatio":0,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02629\",,,,,undefined,":{"symbol":"02629","floatShares":276342331,"roa":"-51.53%","roe":"--","lyrEps":0,"shares":276342331,"dividePrice":0,"high":31.95,"amplitude":0.126609,"preClose":23.3,"low":29,"week52Low":29,"pbRate":"-5.07","psRate":"52.18","week52High":31.95,"institutionHeld":0,"latestPrice":30,"committee":0.938144,"eps":0,"divideRate":0,"volume":9178741,"delay":0,"ttmEps":0,"open":29,"prevYearClose":23.3,"prevWeekClose":23.3,"prevMonthClose":23.3,"prevQuarterClose":23.3,"fiveDayClose":23.3,"twentyDayClose":23.3,"sixtyDayClose":23.3},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1862679398,"yearFounded":2014,"employeeNum":352,"address":"2 Tukang Innovation Grove,#09-02 JTC MedTech Hub,Singapore,Singapore","zipCode":"618305","officePhone":"65 6816 2931"},"stockCompanyDetail":{"websiteUrl":"http://mirxes.com","stockEarnings":[{"period":"1week","weight":0.2876},{"period":"ytd","weight":0.2876}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0693},{"period":"3month","weight":0.0053},{"period":"6month","weight":0.2273},{"period":"1year","weight":0.2508},{"period":"ytd","weight":0.1765}],"compareStock":{"symbol":"HSI","name":"恆生指數"},"description":"MiRXES Holding Company Limited is a micro ribonucleic acid (miRNA) technology company specializing in early cancer detection and precision medicine. It develops and commercializes accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases. Its segments include Infectious diseases and Early detection and precision multi-omics. Its solutions include cancer screening; clinical sequencing; cancer treatment selection, and infectious diseases. Its core product (namely, GASTROClear), two other commercialized products (namely, LUNGClear and Fortitude), and six product candidates at pre-clinical stage. GASTROClear is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. LUNGClear, its lung cancer screening product candidate, is a detection panel consisting of miRNA biomarkers discovered and verified in multi-center studies. It offers complete COVID-19 testing solutions.","exchange":"SEHK","name":"MIRXES-B","nameEN":"MIRXES-B"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"02629\",market:\"HK\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02629\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02629\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02629\",market:\"HK\",delay:false,,,undefined,":{}}}